Reshma Kewalramani serves as the Chief Executive Officer and President for Vertex Pharmaceuticals, Inc.
In this role, Kewalramani leads and executes the company’s strategy and ambitious mission of trans-forming the lives of people with serious diseases. Prior to taking on her role as CEO and President, she was the Chief Medical Officer and Executive Vice President of Global Medicines Development and Medical Affairs.
Kewalramani’s also a member of the Boston University School of Medicine Dean’s Advisory Board, the MGH Board of Trustees, and the Ginkgo Bioworks board of directors. She is a Fellow of the American Society of Nephrology.
In 2021, Kewalramani received the Golden Door Award from the International Institute of New England and was named a New Englander of the Year by the New England Council.
Kewalramani earned her medical degree, with honors, from the seven-year medicine program at the Boston University School of Medicine and completed the General Management Program at Harvard Business School. She completed her internship and residency in internal medicine at the Massachusetts General Hospital (MGH) and her fellowship in nephrology through the MGH and Brigham and Women’s Hospital combined program.
